ARA-290 (Cibinetide) vs TB-500 Fragment 17-23

ARA-290 (Cibinetide): Tissue-protective helix-B fragment of erythropoietin — without the red-blood-cell effects. Typical dose 2,000-8,000 mcg. TB-500 Fragment 17-23: The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects. Typical dose 2000-5000 mcg. Both fall under the Healing & Recovery category.

Stacking ARA-290 (Cibinetide) with TB-500 Fragment 17-23 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

ARA-290 (Cibinetide) is typically dosed: Once daily (SubQ) for Small-fiber neuropathy / nerve healing; Daily or alternate-day for General tissue protection research. TB-500 Fragment 17-23 is typically dosed: Twice weekly SubQ for Injury recovery (extrapolated); Twice weekly SubQ for Tendon/ligament support (extrapolated); Twice weekly for 2-3 weeks for Loading phase (anecdotal).

ARA-290 (Cibinetide): Not FDA approved. In clinical development by Araim Pharmaceuticals. Granted orphan drug designation for sarcoidosis-related conditions. TB-500 Fragment 17-23: Not FDA approved for any human or veterinary use. No clinical trials have been conducted on this specific fragment.